Newsletters
Overcoming the limits of in vivo evaluation with high efficiency of over 70%－A webinar on in vivo evaluation presented by three experts－
18 November 2024
| |
|
|
|
|
Overcoming the limits of in vivo evaluation with high efficiency of over 70%
－A webinar on in vivo evaluation presented by three experts－
|
|
|
After obtaining reproducible data from experiments using cultured cells, in vivo evaluation is necessary for publication. This newsletter is intended for those conducting in vivo evaluation in the future or those seeking more efficient and easier siRNA or miRNA in vivo transfection.
A webinar on in vivo evaluation will also be presented by three experts.
|
|
|
|
<<Highly efficient in vivo experiments in just three steps in your lab>>
|
|
|
|
Do you have any of these concerns?
- ・No laboratory at the P2 level or above
- ・Want to reduce the time and cost associated with multiple administrations of nucleic acids
- ・Want to minimize toxicity and immunogenicity
AteloGene® is a transfection reagent made from atelocollagen, which has high biocompatibility and is characterized by the absence of viruses and liposomes.
It also inhibits the decomposition of nucleic acids, thereby reducing the frequency of administration and the cost of nucleic acids to be administered.
|
|
|
|
|
|
<<Local administration of siRNA to a subcutaneous melanoma tumor model>>
|
|
|
AteloGene® “Quick Gelation” (AGQG) for sustained-release local administration forms a gel in about 10 min after administration, allowing the nucleic acid to remain at the administration site and achieve a sustained release effect for about 1 week.
When luciferase siRNA (Luc siRNA) was administered locally using AGQG to dual luciferase–expressing melanoma cells implanted subcutaneously in mice, luciferase expression was reduced remarkably by over 70% (based on in-house data).
|
|
|
|
|
|
<<Tail vein administration of siRNA to a systemic metastatic prostate cancer model>>
|
|
|
|
Compared with AGQG, AteloGene® Systemic Use (AGS) for systemic administration does not form a gel and delivers nucleic acids throughout the body by tail vein or intraperitoneal administration. Luc siRNA was administered via the tail vein using AGS into a systemic metastatic prostate cancer model stably expressing luciferase, and the delivery effect of siRNA was assessed 1 day later using an imaging device (IVIS). The result indicated that siRNA was efficiently delivered to each tissue in the AGS group (Data were provided by Fumitaka Takeshita, Division Chief, National Cancer Center, and Takahiro Ochiya, Professor, Tokyo Medical University)
|
|
|
|
|
|
<<AteloGene® webinar Information>>
Recent progress in the in vivo evaluation of nucleic acid medicine presented by three experts
For researchers interested in advancing in vivo evaluation.
January 23 (Thursday), 30 (Thursday), and February 6 (Thursday)
17:00–18:00
|
|
|
|
<<Exhibition information>>
We plan to present at the following academic conference in November. Apart from exhibiting various atelocollagen products at the venue, our researchers will present a poster, so please come and visit us.
|
|
The 37th Annual Meeting of the Japanese Society for Alternatives to Animal
Experiments
Period: November 29 (Friday) to December 1 (Sunday)
Venue: Large Hall East, 1st Foor, Light Cube Utsunomiya
Booth: 9 |
|
|
|
|
|
|
|
|
